Biofrontera (NASDAQ:BFRI – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Valuation & Earnings
This table compares Biofrontera and Syndax Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $34.07 million | 0.22 | -$20.13 million | ($15.82) | -0.09 |
| Syndax Pharmaceuticals | $139.71 million | 12.75 | -$209.36 million | ($2.96) | -7.08 |
Biofrontera has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 0 | 0 | 1 | 0 | 3.00 |
| Syndax Pharmaceuticals | 0 | 1 | 9 | 0 | 2.90 |
Biofrontera presently has a consensus target price of $18.00, indicating a potential upside of 1,145.67%. Syndax Pharmaceuticals has a consensus target price of $34.42, indicating a potential upside of 64.20%. Given Biofrontera’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Biofrontera is more favorable than Syndax Pharmaceuticals.
Insider & Institutional Ownership
10.1% of Biofrontera shares are owned by institutional investors. 0.7% of Biofrontera shares are owned by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Profitability
This table compares Biofrontera and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -59.09% | -344.98% | -72.85% |
| Syndax Pharmaceuticals | N/A | -47.88% | -44.00% |
Summary
Syndax Pharmaceuticals beats Biofrontera on 9 of the 14 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
